James C. Mullen
Chief Executive Officer
Mr. Mullen joined Patheon in 2011 as Chief Executive Officer. Prior to joining Patheon, he served as CEO and President at Biogen Idec Inc. from 2003 to 2010, one of the world's largest biotechnology companies. Mr. Mullen was responsible for the merger of Biogen and Idec Pharmaceuticals, serving as CEO and President of Biogen from 2000 to 2002, and Chairman, CEO and President of Biogen until the merger was complete in 2003. Additionally, Mr. Mullen held various operating positions at Biogen prior to becoming CEO, including Vice President, Operations, and several manufacturing and engineering positions over a nine-year period at SmithKline Beckman. Mr. Mullen possesses over 30 years of industry experience, ranging from biotechnology, pharmaceuticals to specialty chemicals, as well as extensive expertise in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions. Currently, he is a Board of Director for Perkins Elmer Inc. and a trustee on The Rivers School, as well as former Chairman of the Biotechnology Industry Association. Mr. Mullen holds a Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute, and a Master of Business Administration from Villanova University.
Antonella Mancuso
President, Global Commercial Operations and Chief Manufacturing Officer
Ms. Mancuso joined Patheon in 2001 as Production Manager of Patheon's facility in Monza, Italy, becoming Site Director in June 2002. She became Director, Italian Operations in January 2005, with responsibility for integrating and managing both the Monza and Ferentino sites. In February 2009, Ms. Mancuso was appointed Senior Vice President & Managing Director, European Operations. Prior to joining Patheon, Ms. Mancuso held progressively senior roles in production and manufacturing during her six years at Bristol-Myers Squibb in Italy. Prior to that, Ms. Mancuso served as Qualified Technical Director with Select Pharma. She began her career in 1991 at Bioprogress in Rome, where her responsibilities included quality control and registration of pharmaceutical products. Ms. Mancuso holds a degree in pharmaceutical chemistry and technology from La Sapienza University of Rome.
Michael Lehmann
President, Global PDS and Interim Executive Vice President, Global Sales & Marketing
Mr. Lehmann joined Patheon in 2012 as President of Global Pharmaceutical Development Services (PDS) and was also later appointed the role of Interim Executive Vice President, Global Sales and Marketing. He was most recently Corporate Senior Vice President and General Manager of the Global Early Development business of Covance from 2005 to 2012, which is one of the world’s largest drug development services companies. In his role, he was responsible for global early development and P&L management; and key accomplishments included executive leadership in strategic deals between Covance, Lilly and Sanofi. Prior to joining Covance, Mr. Lehmann worked for 17 years at GE's Healthcare in key operational and management roles. His career started with a focus in client services, managing large call centers for both external customers and repair technicians. In 1998, he was tasked with assisting in the integration of the company’s MECON acquisition, operational and clinical performance optimization services. Mr. Lehmann progressed through various other comparable roles to emerge as the General Manager of the Multivendor Solutions business in 2003, where he was responsible for facilitating the upkeep and repair of other OEM diagnostic imaging equipment and accessories with complete P&L responsibilities.
Mr. Lehmann holds a M.B.A. from Marquette University and a B.S. in mechanical engineering from the Catholic University of America.
Geoffrey M. Glass
President, Product and Technology Commercialization
Mr. Glass is responsible for Patheon’s product business unit. This includes the research, development and commercialization of products on a worldwide basis across the landscape of nutritionals, over-the-counter and prescription medicines. He originally joined Patheon as Senior Vice President, Strategy, Corporate Development and Integration and was later promoted to Executive Vice President, Global Sales and Marketing in 2009. Mr. Glass was appointed to his current position as President of Product and Technology Commercialization in 2012. Prior to joining Patheon, he spent about five years on the Executive Team at Valeant Pharmaceuticals International. Mr. Glass was the Senior Vice President, Asian Operations where he had responsibilities for all of Valeant's business affairs in the region, which included over 250 products in 14 countries. Prior to leading the Asian business, Mr. Glass also served as Senior Vice President and Chief Information Officer of Valeant Pharmaceuticals. In addition, Mr. Glass was the Global Leader of Life Sciences Operations Excellence Practice for Cap Gemini (formerly Ernst & Young LLP Consulting). During his tenure at Cap Gemini, Mr. Glass led global teams through the successful implementation of business and IT transformations at a number of leading life sciences organizations. Mr. Glass earned his Bachelor of Arts in economics and political science at the University of Arizona.
Aqeel Fatmi, Ph.D.
Executive Vice President, Global Research & Development and Chief Scientific Officer
Dr. Fatmi joined Patheon in 2013 as Executive Vice President, Global Research & Development of the proprietary products and technology business as well as Patheon’s Chief Scientific Officer. He possesses over 30 years of experience in the pharmaceutical industry and has held several global leadership positions focused on the areas of research & development and supply chain/operations management. Most recently, Dr. Fatmi served on Banner Pharmacaps’ global leadership team as Global Vice President, Research & Development and Operations. In this role, he managed the development, registration, tech transfer and launch of new and existing proprietary and customer products, as well as the oversight of all of the company's production operations. Dr. Fatmi was a founder of the Georgia Combinatorial Chemistry Center at Georgia State University in Atlanta with a focus to discover small molecule drugs for cancer, HIV and other infectious diseases. He spent a major part of his career at Solvay Pharmaceuticals, where he served as Senior Vice President of Research & Development, being responsible for the development, approval and launch of new drugs. Dr. Fatmi holds a Ph.D. in Medicinal Chemistry from The University of Georgia, Athens. After graduation Dr. Fatmi was a National Science Foundation Post Doctoral Fellow for one year at The University of Georgia.
Paul M. Garofolo
Executive Vice President, Global PDS Operations
Mr. Garofolo serves as Executive VP, Global PDS Operations, bringing over 18 years of experience in technology and management consulting leadership. He joined Patheon in 2008 as Chief Information Officer and later served as Chief Technology Officer overseeing operational excellence, IT, engineering and procurement. Mr. Garofolo transitioned from CTO into PDS in 2011 to help implement the new business operations function and was later promoted to Executive VP of Global PDS Operations. Prior to joining Patheon, he served as Chief Information Officer at Valeant Pharmaceuticals International Inc., as well as Chief Technology Officer for Broadlane Group, the fourth largest group purchasing organization within the U.S. healthcare market. He also worked in the management consulting industry for both Ernst & Young and Oracle. Mr. Garofolo holds a B.S./B.A. from the University of Arizona with a concentration in management information systems.
Stuart Grant
Executive Vice President, Chief Financial Officer
Mr. Grant joined Patheon in 2012 after serving as Senior Vice President and Chief Financial Officer of BioCryst Pharmaceuticals, Inc., where he was a key player in the creation and execution of a company-wide strategy that stabilized, funded and enabled commercialization activities. Prior to BioCryst, Mr. Grant was Group Chief Financial Officer for Serono SA, Europe's largest biotechnology company. Over 12 years, he served in various senior operating and financial roles, including Finance Director for Swiss Manufacturing Operations and then General Manager of the company's manufacturing laboratories. Mr. Grant also spent 15 years in finance at Digital Equipment Corporation, and several years working as a tax consultant and senior auditor for Price Waterhouse in Glasgow, Scotland.
Michael E. Lytton
Executive Vice President, Corporate Development and Strategy, and General Counsel
Mr. Lytton leads the company's strategy and corporate development activities, as well as its global legal team. Prior to joining Patheon, Mr. Lytton was Executive Vice President, Corporate and Business Development of Biogen Idec from 2008-2011. From 2001 to 2008, Mr. Lytton was General Partner with Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic and life science tool companies. He practiced law from 1984-2000 and specialized in representing biomedical companies; he was Partner and a member of the Executive Committee of the law firm Edwards Wildman Palmer and was Partner of the law firm Wilmer Hale. Mr. Lytton served as Chairman of the Board of Santhera Pharmaceuticals AG from 2004-2011, and has also served on various boards of many other academic, nonprofit and private and public for-profit companies. Mr. Lytton holds an undergraduate degree from Princeton University, a Master of Science degree in epidemiology from the London School of Hygiene and Tropical Medicine at the University of London, U.K., where he was a Fulbright Scholar; he also has a Juris Doctor degree from Harvard Law School.
Harry Gill
Senior Vice President, Quality and Continuous Improvement
Mr. Gill serves as Senior Vice President, Quality and Continuous Improvement. He joined Patheon in 2010 as Global Vice President of Operational Excellence and North America Vice President of Business Management, and was later promoted to his current position. He brings over 25 years of experience in quality, plant operations, technical services and operational excellence, having held various positions at Wyeth (now known as Pfizer Pharmaceuticals) and Baxter Healthcare Corporation. In addition, he has eight years of combined international experience in Asia and Puerto Rico. Mr. Gill received a Bachelor of Science in biology from Milligan College and a Masters of Science in microbiology from East Tennessee State University.
Rebecca Holland New
Chief HR Officer and Senior Vice President, Human Resources and Corporate Communications
Mrs. Holland New serves as Chief HR Officer and Senior Vice President, Human Resources and Corporate Communications, overseeing the global human resources organization which includes global compensation and benefits. She has a wealth of experience leading and developing business leadership, strategies and operational processes within growing global healthcare organizations. Most recently, she was Global Vice President, Human Resources at Bausch & Lomb. Before becoming Global VP, HR at Bausch & Lomb, she held global human resources leadership positions at the company’s business operations, talent, corporate and pharmaceutical business units as well as global research and development. Prior to joining Bausch & Lomb, Mrs. Holland New held human resources leadership positions at Novo Nordisk and Bristol-Myers Squibb. Mrs. Holland New earned a Master of Industrial and Labor Relations as well as a Bachelor of Science in economics, marketing and finance from Cornell University. In addition, she completed course work toward a Ph.D./Master of Science in organizational psychology from Columbia University and Rutgers University.
Gary L. Shope
Chief of Staff
Mr. Shope serves as Chief of Staff to Patheon's Executive Committee. Previously, he worked as an international business recruiter for the Riyadh Technology Valley in Saudi Arabia. Mr. Shope has also served as Vice President and officer for the Research Triangle Park Foundation, as well as owner and operator of the internationally recognized Research Triangle Park. Furthermore, he directed international business development at the North Carolina Department of Commerce, including direct activity with two NC governors. In addition, Mr. Shope served as principal of Schottenstein, Zox, & Dunn, a law firm headquartered in Columbus, OH. He earned a Masters of Public Administration from the University of North Carolina at Chapel Hill, and attended a one-year program at Yale University after graduating from West Virginia Wesleyan College.